American Society of Hirudotherapy

Flap infection associated with medicinal leeches in reconstructive surgery: two new drug-resistant organisms

Bibbo C, Fritsche T, Stemper M, Hall M (2013) · Journal of Reconstructive Microsurgery · 2 patients

Case-level evidence: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE Very LowCase reportInfections after leech therapy

Study Profile

Design
two-case report with management protocol review (Marshfield Clinic, Wisconsin)
Patients
2
Presentation and intervention
Standard leech therapy in reconstructive surgery patients with subsequent identification of two new multidrug-resistant organisms causing flap infection
Outcome
Two new multidrug-resistant organisms identified from medicinal leech therapy resulting in flap infection; suspected leech-borne infection evaluation and management protocol presented
Follow-up duration
Postoperative infection course

Key Findings

  • Two new multidrug-resistant organisms identified
  • Beyond traditional Aeromonas hydrophila coverage
  • Comorbidities: arthropathy, obesity (morbid)
  • Management protocol for suspected leech-borne resistant infections
  • Supports antibiogram-guided empiric therapy

Limitations

  • Only 2 cases - cannot characterize population resistance
  • Single institution experience
  • Specific organisms not detailed in abstract
  • Underlying comorbidities may select for resistant flora
  • Cannot recommend universal protocol changes

Clinical Implications

Bibbo 2013 documents two novel multidrug-resistant organisms from medicinal leech therapy and provides clinical management protocol. For US clinicians under K040187, the case report highlights the need for individualized microbiologic evaluation in suspected leech-borne infections, particularly in patients with significant comorbidities (obesity, joint disease).

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.